Literature DB >> 2464742

c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells.

E V Prochownik1, J Kukowska, C Rodgers.   

Abstract

Friend murine erythroleukemia (F-MEL) cells were transfected with a plasmid bearing tandemly arranged mouse c-myc antisense and dihydrofolate reductase transcription units. Sixteen clones were isolated, each containing unrearranged c-myc sequences and expressing high levels of antisense transcripts. All antisense clones examined contained reduced amounts of cytoplasmic endogenous c-myc transcripts. The kinetics of reaccumulation of endogenous c-myc mRNA during a 24-h exposure to dimethyl sulfoxide (DMSO) were also retarded and the ultimate transcript levels attained were less than in control cells. Antisense clones grew as well as control F-MEL cells in medium containing 10% fetal calf serum but at only a half and a quarter of the control rates in media containing 5 and 2% serum, respectively. Antisense clones differentiated faster and to a greater degree than control cells following DMSO exposure. myc antisense transcript expression was increased by growing cells in methotrexate, which resulted in an enhanced response to DMSO. Fluorescence-activated cell sorter (FACS) analysis of cellular DNA content indicated that a greater fraction of antisense nuclei contained a G0/G1 2n DNA content following a 24-h exposure to DMSO. When density-arrested antisense clones were diluted into fresh medium to allow reentry into the cell cycle, they incorporated less [3H]thymidine than control cells. FACS analysis showed that this was because only a portion of the cell population was entering S phase. Whereas control cells did not increase in size following release from density arrested antisense cells contained a subpopulation which were initially smaller and which eventually attained the same size as control cells. Quiescent antisense cells thus comprise two populations, each arrested at a different point in G1. Dilutional replating allowed both populations to reenter the cell cycle. We propose a model which postulates that certain minimal myc levels are necessary for cells to traverse G1. Those with insufficient levels, due, for example, to antisense inhibition, are unable to completely traverse G1 during density arrest and synchronize at an earlier point than do control cells. This earlier point may be along the differentiation pathway and may account for the greater responsiveness of antisense cells to DMSO induction. This model postulates that F-MEL cells overexpressing myc fail to differentiate because myc levels are never sufficiently low enough to allow cells to enter the differentiation pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464742      PMCID: PMC365424          DOI: 10.1128/mcb.8.9.3683-3695.1988

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

1.  Significance of the cell cycle in commitment of murine erythroleukemia cells to erythroid differentiation.

Authors:  R Geller; R Levenson; D Housman
Journal:  J Cell Physiol       Date:  1978-05       Impact factor: 6.384

Review 2.  Erythroleukemic differentiation.

Authors:  P A Marks; R A Rifkind
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

3.  Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide.

Authors:  C Friend; W Scher; J G Holland; T Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1971-02       Impact factor: 11.205

4.  Coupling of growth arrest and differentiation at a distinct state in the G1 phase of the cell cycle: GD.

Authors:  R E Scott; D L Florine; J J Wille; K Yun
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

5.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

6.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.

Authors:  K Kelly; B H Cochran; C D Stiles; P Leder
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  Differential expression of the amv gene in human hematopoietic cells.

Authors:  E H Westin; R C Gallo; S K Arya; A Eva; L M Souza; M A Baluda; S A Aaronson; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

8.  Isolation and expression of an altered mouse dihydrofolate reductase cDNA.

Authors:  C C Simonsen; A D Levinson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

9.  A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1.

Authors:  R Heikkila; G Schwab; E Wickstrom; S L Loke; D H Pluznik; R Watt; L M Neckers
Journal:  Nature       Date:  1987 Jul 30-Aug 5       Impact factor: 49.962

10.  Coupling of proadipocyte growth arrest and differentiation. II. A cell cycle model for the physiological control of cell proliferation.

Authors:  R E Scott; B J Hoerl; J J Wille; D L Florine; B R Krawisz; K Yun
Journal:  J Cell Biol       Date:  1982-08       Impact factor: 10.539

View more
  40 in total

Review 1.  The Max network gone mad.

Authors:  T A Baudino; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Mad1 function is regulated through elements within the carboxy terminus.

Authors:  G Barrera-Hernandez; C M Cultraro; S Pianetti; S Segal
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription.

Authors:  Adam Siddiqui-Jain; Cory L Grand; David J Bearss; Laurence H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

4.  The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation.

Authors:  M J Smith; D C Charron-Prochownik; E V Prochownik
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

5.  Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells.

Authors:  M D Sklar; E Thompson; M J Welsh; M Liebert; J Harney; H B Grossman; M Smith; E V Prochownik
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

6.  Deregulation of common genes by c-Myc and its direct target, MT-MC1.

Authors:  Kenneth R Rogulski; Debra E Cohen; David L Corcoran; Panayiotis V Benos; Edward V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

7.  c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.

Authors:  H Wang; S Mannava; V Grachtchouk; D Zhuang; M S Soengas; A V Gudkov; E V Prochownik; M A Nikiforov
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

8.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

9.  Biologic and therapeutic significance of MYB expression in human melanoma.

Authors:  N Hijiya; J Zhang; M Z Ratajczak; J A Kant; K DeRiel; M Herlyn; G Zon; A M Gewirtz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

10.  The human cut homeodomain protein represses transcription from the c-myc promoter.

Authors:  D Dufort; A Nepveu
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.